Overall Survival Data of the MONARCH-2 Trial in HR+/HER2- Breast Cancer

October 2, 2019
George Sledge, Jr., MD

George Sledge, Jr., MD, discusses the overall survival data of the phase III MONARCH-2 trial in advanced hormone receptor-positive, HER2-negative breast cancer.

George Sledge, Jr., MD, professor of medicine (oncology) at Stanford University Medical Center, discusses the overall survival (OS) data of the phase III MONARCH-2 trial in advanced hormone receptor (HR)—positive, HER2-negative breast cancer.

Data presented at the 2019 ESMO Congress demonstrated that the combination of abemaciclib (Verzenio) and fulvestrant (Faslodex) demonstrated a median 9.4-month OS benefit versus fulvestrant and placebo in patients with advanced HR—positive, HER2-negative breast cancer who progressed on prior endocrine therapy. These data are both statistically significant and clinically important, says Sledge.

At a median follow-up of 47.7 months, the median OS with the combination of abemaciclib and fulvestrant was 46.7 months versus 37.3 months with placebo/fulvestrant (HR, 0.757; 95% CI, 0.606-0.945;P